Starling Oncology Inc. (STLN) is a Medical/Nursing Services company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for STLN, including 2 SEC filings and 1 earnings update. The most recent was published Nov 5, 2026.
STLN rankings
Financial highlights
Full financials- Revenue, TTM
- $620.45M
- Revenue growth
- +34.6%
- Net income, TTM
- -$35.54M
- Net margin
- -5.7%
- Free cash flow, TTM
- $18.83M
- Cash
- $36.90M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks3+100%
2026-05-172026-11-08
Mix390d
- SEC Filings2(67%)
- Earnings1(33%)
Activity · 52 weeks32 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
3 items- SECSEC Form 10-Q filed by Starling Oncology Inc.10-Q - Starling Oncology, Inc. (0001799191) (Filer)
- SECStarling Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Starling Oncology, Inc. (0001799191) (Filer)
- PRStarling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 GuidanceCERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ:STLN) ("STLN" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended September 30, 2026 and updated it's full-year 2026 guidance. Recent Operational Highlights Specialty Pharmacy Revenue was $109 million, up 44 percent year over year, and gross margin was 24 percent. Continued increase in the capture rate of fills written by Starling physicians was the primary contributor to year-over-year revenue growth in the specialty pharmacy.Capitated revenue grew 40 percent year over year in the third quarter, and our m
STLN FAQ
10 questionsWhat does Starling Oncology Inc. do?
Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.2 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and...What is the latest news on STLN?
In the last 30 days Quantisnow tracked 3 wire items for STLN: 2 SEC filings and 1 earnings update. The most recent was published on November 5, 2026.What is STLN revenue?
Starling Oncology Inc. (STLN) reported $620.45M of revenue for the twelve months ended Sep 30, 2026. That is up 34.6% from the year before. Revenue for fiscal 2025 was $502.73M.Is STLN profitable?
No. Starling Oncology Inc. reported a net loss of $35.54M for the twelve months ended Sep 30, 2026.How much cash and debt does STLN have?
Starling Oncology Inc. reported $36.90M in cash and cash equivalents and $72.52M of debt on its most recent balance sheet in SEC filings.Where does STLN stock trade?
Starling Oncology Inc. (STLN) is listed on NASDAQ.What sector and industry is STLN in?
Starling Oncology Inc. operates in the Health Care sector, Medical/Nursing Services industry.When did Starling Oncology Inc. go public?
Starling Oncology Inc. (STLN) completed its IPO in 2020.What companies are similar to STLN?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), CHE (Chemed Corp), HIMS (Hims & Hers Health Inc.), LFST (LifeStance Health Group Inc.), OPCH (Option Care Health Inc.). Compare STLN side-by-side with any of them on Quantisnow.How can I track STLN on Quantisnow?
Quantisnow aggregates Starling Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STLN to receive live email and push alerts on every new disclosure.